Early research on a new approach to protecting against malaria is offering promising, potentially long-lasting results against the persistent parasite that sickens hundreds of millions people each year. The approach uses a cytomegalovirus-based platform that's already being used in vaccines being developed to battle HIV and tuberculosis. This new vaccine reduced the malaria-causing parasite's release from the liver and into the blood of infected rhesus macaques by 75 to 80 percent, reports a paper published in the journal PLOS ONE.
- PLOS ONE
- Military Infectious Diseases Research Program, National Institutes of Health